Alaska Permanent Fund is the famous VC, which was founded in 1976. The main office of represented VC is situated in the Juneau. The company was established in North America in United States.
Opposing the other organizations, this Alaska Permanent Fund works on 7 percentage points less the average amount of lead investments. The higher amount of exits for fund were in 2017. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The typical startup value when the investment from Alaska Permanent Fund is more than 1 billion dollars. The real fund results show that this VC is 2 percentage points more often commits exit comparing to other companies. The important activity for fund was in 2017.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Alaska Permanent Fund, startups are often financed by Flagship Pioneering, ARCH Venture Partners, Fidelity Management and Research Company. The meaningful sponsors for the fund in investment in the same round are Flagship Pioneering, ARCH Venture Partners, Yukon Partners. In the next rounds fund is usually obtained by Flagship Pioneering, Baillie Gifford, Venrock.
We can highlight the next thriving fund investment areas, such as Therapeutics, IaaS. Among the most popular portfolio startups of the fund, we may highlight Juno Therapeutics, Indigo Agriculture, Denali Therapeutics. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 1 or 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.
The overall number of key employees were 4.
Funds with similar focus
|Batu Capital||New York, New York, United States|
|Cascade Seed Fund||Bend, Oregon, United States|
|Costella Kirsch||California, Menlo Park, United States|
|Disruptive Labs||California, Santa Monica, United States|
|Domo Investment||Chengdu, China, Sichuan|
|Fraser Mackenzie||Canada, Ontario, Toronto|
|Furui Caizhi Guquan Jijin||China, Jiangsu, Nanjing|
|Kendu Partners Company||-|
|Padberg & Partners||New York, New York, United States|
|Princeton Biopharma Capital Partners||New York, New York, United States|
|SMBC Nikko Securities Japan||-|
|Sprint||Kansas, Overland Park, United States|
|Taiho Pharmaceutical Co||Japan, Tokyo|
|Wanxiang America||Elgin, Illinois, United States|
|Xinrong Voyage Fund||-|
|Yike Zongheng||Beijing, Beijing, China|
|Zhejiangsheng Chanye Jijin||China, Hangzhou, Zhejiang|
|01 Dec 2021||Anchorage, Alaska, United States|
|$370M||18 Nov 2021||Pennsylvania, United States|
Repertoire Immune Medicines
|$189M||13 Apr 2021||Cambridge, Massachusetts, United States|
|$230M||12 Jan 2021||Cambridge, Massachusetts, United States|
|$360M||03 Aug 2020||Boston, Massachusetts, United States|
|$700M||23 Jun 2020||Seattle, Washington, United States|
|$250M||18 Sep 2018||Boston, Massachusetts, United States|
|$76M||29 Nov 2017||San Francisco, California, United States|
|$200M||24 Oct 2017||San Francisco, California, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.